newsfilter
← Latest News
GlobeNewswire·

Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates

AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025AUCATZYL® UK launch underway following successful